Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pulmonx (LUNG) Research & Development (2019 - 2025)

Pulmonx has reported Research & Development over the past 7 years, most recently at $4.8 million for Q3 2025.

  • Quarterly Research & Development rose 29.43% to $4.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $18.9 million through Sep 2025, up 8.27% year-over-year, with the annual reading at $17.6 million for FY2024, 2.82% down from the prior year.
  • Research & Development was $4.8 million for Q3 2025 at Pulmonx, down from $5.3 million in the prior quarter.
  • Over five years, Research & Development peaked at $5.7 million in Q2 2023 and troughed at $2.8 million in Q3 2021.
  • The 5-year median for Research & Development is $4.0 million (2024), against an average of $4.2 million.
  • Year-over-year, Research & Development skyrocketed 145.86% in 2021 and then decreased 11.28% in 2024.
  • A 5-year view of Research & Development shows it stood at $3.7 million in 2021, then increased by 5.26% to $3.9 million in 2022, then fell by 0.18% to $3.9 million in 2023, then increased by 2.7% to $4.0 million in 2024, then increased by 21.12% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Research & Development are $4.8 million (Q3 2025), $5.3 million (Q2 2025), and $4.8 million (Q1 2025).